Savant Capital LLC Sells 35,838 Shares of Astrazeneca Plc $AZN

Savant Capital LLC trimmed its position in shares of Astrazeneca Plc (NYSE:AZN) by 66.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,864 shares of the company’s stock after selling 35,838 shares during the period. Savant Capital LLC’s holdings in Astrazeneca were worth $3,135,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of AZN. Kestra Investment Management LLC lifted its stake in Astrazeneca by 1.9% during the fourth quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock worth $595,000 after purchasing an additional 63 shares during the period. Luken Investment Analytics LLC lifted its stake in Astrazeneca by 4.3% during the fourth quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock worth $274,000 after purchasing an additional 64 shares during the period. Addison Advisors LLC lifted its stake in Astrazeneca by 3.9% during the fourth quarter. Addison Advisors LLC now owns 1,736 shares of the company’s stock worth $305,000 after purchasing an additional 65 shares during the period. Western Wealth Management LLC lifted its stake in Astrazeneca by 2.5% during the fourth quarter. Western Wealth Management LLC now owns 2,887 shares of the company’s stock worth $507,000 after purchasing an additional 71 shares during the period. Finally, Soltis Investment Advisors LLC lifted its stake in Astrazeneca by 2.2% during the fourth quarter. Soltis Investment Advisors LLC now owns 3,470 shares of the company’s stock worth $609,000 after purchasing an additional 76 shares during the period. 20.35% of the stock is currently owned by institutional investors.

Astrazeneca Stock Performance

Shares of Astrazeneca stock opened at $185.50 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The firm has a market cap of $287.70 billion, a P/E ratio of 27.85, a P/E/G ratio of 1.48 and a beta of 0.26. The firm has a 50 day simple moving average of $191.27 and a 200 day simple moving average of $183.97. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Sell-side analysts predict that Astrazeneca Plc will post 10.26 earnings per share for the current fiscal year.

Analyst Ratings Changes

AZN has been the subject of several recent analyst reports. Weiss Ratings initiated coverage on shares of Astrazeneca in a report on Wednesday, March 11th. They set a “buy (b)” rating for the company. Barclays raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a report on Thursday, May 14th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Astrazeneca presently has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.